99 related articles for article (PubMed ID: 2865088)
21. Renal effects of nitrendipine monotherapy in essential hypertension.
Thananopavarn C; Golub MS; Eggena P; Barrett JD; Sambhi MP
J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1032-6. PubMed ID: 6085362
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology and pharmacokinetics of prizidilol in hypertensive patients.
Chaignon M; Decourt S; Guelpa G; Rocher I; Flouvat B; Guédon J
J Cardiovasc Pharmacol; 1983; 5(6):1068-73. PubMed ID: 6196556
[TBL] [Abstract][Full Text] [Related]
23. [Enalapril in the treatment of essential arterial hypertension].
Pérez-Grovas H; Fernández M; Arriaga J; Herrera-Acosta J
Arch Inst Cardiol Mex; 1986; 56(5):379-90. PubMed ID: 3026264
[TBL] [Abstract][Full Text] [Related]
24. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
[TBL] [Abstract][Full Text] [Related]
25. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
Man in't Veld AJ; Schalekamp MA
Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
[TBL] [Abstract][Full Text] [Related]
26. Prizidilol (SKF 92657) in primary hypertension.
Karlberg BE; Larsson R; Ohman KP
Clin Sci (Lond); 1981 Dec; 61 Suppl 7():461s-464s. PubMed ID: 7188585
[TBL] [Abstract][Full Text] [Related]
27. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.
Semplicini A; Ceolotto G; Sartori M; Maresca A; Baritono E; De Toni R; Paparella I; Calò L
J Nephrol; 2002; 15(5):489-96. PubMed ID: 12455714
[TBL] [Abstract][Full Text] [Related]
28. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
[TBL] [Abstract][Full Text] [Related]
29. Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers.
Eggertsen R; Hansson L
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):411-23. PubMed ID: 2864319
[TBL] [Abstract][Full Text] [Related]
30. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
31. Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.
Pascual JM; Rodilla E; Miralles A; Gonzalez C; Redon J
J Hypertens; 2006 Nov; 24(11):2277-84. PubMed ID: 17053551
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
Antonaccio MJ; High J; DeForrest JM; Sybertz E
J Pharmacol Exp Ther; 1986 Jul; 238(1):378-87. PubMed ID: 2873238
[TBL] [Abstract][Full Text] [Related]
33. Effect of long-term nifedipine treatment on body fluid composition in essential hypertension.
Toftdahl DB; Andersen GS
J Hum Hypertens; 1989 Jun; 3(3):203-6. PubMed ID: 2769676
[TBL] [Abstract][Full Text] [Related]
34. [Behavior of arterial pressure, hemodynamic parameters, sympathetic nervous system activity and plasma volume during treatment with a vasodilating and beta-blocking drug in essential hypertension patients].
Fariello R; Alicandri C; Agabiti-Rosei E; Romanelli G; Montini E; Muiesan ML; Minniti P; Castellano M; Beschi M; Boni E; Zaninelli A; Micheli P; Platto L; Leto Di Priolo S; Muiesan G
Boll Soc Ital Cardiol; 1981; 26(11):1871-4. PubMed ID: 6129877
[No Abstract] [Full Text] [Related]
35. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934
[TBL] [Abstract][Full Text] [Related]
36. Nephroprotection by antihypertensive agents.
Schmieder RE
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic and pharmacokinetic studies on prizidilol and nipradilol (K-351), antihypertensive drugs with combined vasodilator and beta-adrenoceptor blocking actions, in rabbits.
Kawashima K; Watanabe TX; Sokabe H
Jpn J Pharmacol; 1984 Dec; 36(4):519-26. PubMed ID: 6151998
[TBL] [Abstract][Full Text] [Related]
38. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
[TBL] [Abstract][Full Text] [Related]
39. Effects of prizidilol (SKF 92657) on blood pressure, haemodynamics, sympathetic nervous system activity and plasma volume in essential hypertension.
Fariello R; Alicandri CL; Agabiti-Rosei E; Romanelli G; Castellano M; Beschi M; Platto L; Di Priolo SL; Muiesan G
Clin Sci (Lond); 1981 Dec; 61 Suppl 7():465s-468s. PubMed ID: 7318352
[TBL] [Abstract][Full Text] [Related]
40. [Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
Hartmann HG; Schumacher H
Schweiz Med Wochenschr; 1985 Jul; 115(27-28):939-44. PubMed ID: 2862703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
